Trials / Completed
CompletedNCT06160167
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,204 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants with MM not treated with IMiDs. The study will use de-identified data from electronic medical records in the Flatiron Health database.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMiD treatment | Participants with MM treated with IMiDs |
| DRUG | No IMiD treatment | Participants with MM not treated with IMiDs |
| DRUG | Systemic therapy | Participants with MM treated with systemic therapy |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2024-08-01
- Completion
- 2024-08-01
- First posted
- 2023-12-07
- Last updated
- 2024-08-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06160167. Inclusion in this directory is not an endorsement.